Core Framework & Diagram What Is Tumor Microenvironment?
July 6, 2026Core Framework & Diagram What Are Tumor Antigens?
July 7, 2026
The 'evidence' of cancer cells: the abnormal proteins that reveal their identity
By the Editors 1-min read
Have you ever wondered how T cells know which cell to attack? The answer lies in 'antigens' — protein fragments displayed on cell surfaces, the cell's 'name card.' Normal cells display name cards T cells recognize and let pass. But cancer cells, due to gene mutations, display name cards that have problems: some are distorted (mutated protein fragments), some shouldn't appear under normal circumstances (carcinoembryonic antigens), some are excessive (overexpressed proteins).
These abnormal name cards are tumor antigens. They're the targets the immune system uses to recognize cancer cells, and the design basis of cancer vaccines and some immunotherapies.
More interestingly: each person's cancer cell mutations are different, so tumor antigens are also different — this is the scientific foundation of 'individualized tumor vaccines,' the cutting-edge direction in oncology.
KEY TAKEAWAYS
01
Tumor antigens are the molecular basis the immune system uses to distinguish cancer cells from normal cells — cancer cells produce abnormal protein fragments through gene mutations, displayed via MHC-I, becoming T cell recognition targets.
02
Neoantigens are the highest-value treatment targets: exist only in cancer cells, theoretically zero damage to normal tissue when targeted — the core of individualized vaccines and ACT therapy.
03
Each patient's tumor mutations are unique, so their neoantigen profiles are also unique — the fundamental reason 'individualized tumor vaccines' became a scientifically feasible direction.
04
HER2 is the most successful transformation case from TAA to precision treatment — Trastuzumab not only inhibits signaling but also recruits NK cells for ADCC-based killing of cancer cells.
05
Common clinical tumor markers (CEA, AFP, PSA, etc.) mostly belong to TAAs or carcinoembryonic antigens — valuable as diagnostic/surveillance indicators, but as treatment targets they carry normal tissue off-target toxicity risks.
06
The individualized cancer immunotherapy technology roadmap has matured: sequencing → predict neoantigens → synthesize vaccine/activate T cells → combine checkpoint inhibitors. mRNA technology makes this pathway realistically feasible.
Art 71
The Immune Surveillance Theory
→
Art 72
The Cancer Immunoediting Theory
→
